Across clinical studies, regimens with EMEND or EMEND for Injection
were generally well tolerated
The overall safety profile of EMEND was evaluated in approximately 3,800 patients.
Most common clinical adverse events — moderately emetogenic chemotherapy
Most common clinical adverse events — highly emetogenic chemotherapy
The most frequent clinical adverse events reported in patients receiving EMEND for Injection were infusion site pain (7.6%), headache (3.0%), and infusion site induration (1.5%).
